571 related articles for article (PubMed ID: 26177117)
1. Influence of Genetic Polymorphisms on Clopidogrel Response and Clinical Outcomes in Patients with Acute Ischemic Stroke CYP2C19 Genotype on Clopidogrel Response.
Han Y; Lv HH; Liu X; Dong Q; Yang XL; Li SX; Wu S; Jiang JM; Luo Z; Zhu DS; Zhang Y; Zheng Y; Guan YT; Xu JF
CNS Neurosci Ther; 2015 Sep; 21(9):692-7. PubMed ID: 26177117
[TBL] [Abstract][Full Text] [Related]
2. Influence of CYP2C19 polymorphisms on platelet reactivity and clinical outcomes in ischemic stroke patients treated with clopidogrel.
Qiu LN; Sun Y; Wang L; Han RF; Xia XS; Liu J; Li X
Eur J Pharmacol; 2015 Jan; 747():29-35. PubMed ID: 25489921
[TBL] [Abstract][Full Text] [Related]
3. Concomitant Use of Proton Pump Inhibitors and Clopidogrel Is Not Associated with Adverse Outcomes after Ischemic Stroke in Chinese Population.
Yi X; Zhou Q; Wang C; Lin J; Cheng W; Chi L
J Stroke Cerebrovasc Dis; 2016 Dec; 25(12):2859-2867. PubMed ID: 27546731
[TBL] [Abstract][Full Text] [Related]
4. Routine assessment of on-clopidogrel platelet reactivity and gene polymorphisms in predicting clinical outcome following drug-eluting stent implantation in patients with stable coronary artery disease.
Viviani Anselmi C; Briguori C; Roncarati R; Papa L; Visconti G; Focaccio A; De Micco F; Latronico MV; Pagnotta P; Condorelli G
JACC Cardiovasc Interv; 2013 Nov; 6(11):1166-75. PubMed ID: 24262617
[TBL] [Abstract][Full Text] [Related]
5. Impact of CYP2C19 Polymorphisms on Clinical Outcomes and Antiplatelet Potency of Clopidogrel in Caucasian Poststroke Survivors.
Tomek A; Matʼoška V; Frýdmanová A; Magerová H; Šrámek M; Paulasova-Schwabová J; Růžičková T; Janský P; Šarbochová I; Hadačová I; Kaplan V; Lacinová Z; Táborský L; Serebruany V
Am J Ther; 2018; 25(2):e202-e212. PubMed ID: 29509167
[TBL] [Abstract][Full Text] [Related]
6. Variant recurrent risk among stroke patients with different CYP2C19 phenotypes and treated with clopidogrel.
Sun W; Li Y; Li J; Zhang Z; Zhu W; Liu W; Cai Q; Wang X; Cao L; Bai W; Fan X; Ma M; Guo R; Liu X; Xu G
Platelets; 2015; 26(6):558-62. PubMed ID: 25207801
[TBL] [Abstract][Full Text] [Related]
7. CYP2C19 and CES1 polymorphisms and efficacy of clopidogrel and aspirin dual antiplatelet therapy in patients with symptomatic intracranial atherosclerotic disease.
Hoh BL; Gong Y; McDonough CW; Waters MF; Royster AJ; Sheehan TO; Burkley B; Langaee TY; Mocco J; Zuckerman SL; Mummareddy N; Stephens ML; Ingram C; Shaffer CM; Denny JC; Brilliant MH; Kitchner TE; Linneman JG; Roden DM; Johnson JA
J Neurosurg; 2016 Jun; 124(6):1746-51. PubMed ID: 26587656
[TBL] [Abstract][Full Text] [Related]
8. Genotyping, Platelet Activation, and Cardiovascular Outcome in Patients after Percutaneous Coronary Intervention: Two Pieces of the Puzzle of Clopidogrel Resistance.
Siasos G; Oikonomou E; Vavuranakis M; Kokkou E; Mourouzis K; Tsalamandris S; Zaromitidou M; Kioufis S; Tsigkou V; Deftereos S; Stefanadis C; Tousoulis D
Cardiology; 2017; 137(2):104-113. PubMed ID: 28329746
[TBL] [Abstract][Full Text] [Related]
9. Association between platelet function and recurrent ischemic vascular events after TIA and minor stroke
.
Zhang J; Zhang J; Sun H; Ming T; Liu X; Cong Y; Li F; Li Z
Int J Clin Pharmacol Ther; 2017 Oct; 55(10):789-797. PubMed ID: 28766499
[TBL] [Abstract][Full Text] [Related]
10. Dual therapy with clopidogrel and aspirin prevents early neurological deterioration in ischemic stroke patients carrying CYP2C19*2 reduced-function alleles.
Lin J; Han Z; Wang C; Yi X; Chai Z; Zhou Q; Huang R
Eur J Clin Pharmacol; 2018 Sep; 74(9):1131-1140. PubMed ID: 29804161
[TBL] [Abstract][Full Text] [Related]
11. Effect of CYP2C19*2 and *3 on clinical outcome in ischemic stroke patients treated with clopidogrel.
Wang Y; Cai H; Zhou G; Zhang Z; Liu X
J Neurol Sci; 2016 Oct; 369():216-219. PubMed ID: 27653892
[TBL] [Abstract][Full Text] [Related]
12. The impact of gene polymorphism and high on-treatment platelet reactivity on clinical follow-up: outcomes in patients with acute coronary syndrome after drug-eluting stent implantation.
Liang ZY; Han YL; Zhang XL; Li Y; Yan CH; Kang J
EuroIntervention; 2013 Jul; 9(3):316-27. PubMed ID: 23872648
[TBL] [Abstract][Full Text] [Related]
13. [Relevance of CYP2C19 2 regarding platelet reactivity in patients with acute coronary syndrome treated with clopidogrel].
Cano P; Consuegra-Sánchez L; Conesa P; Torres-Moreno D; Jaulent L; Dau D; Picó F; Villegas M
Med Clin (Barc); 2014 Jul; 143(1):6-12. PubMed ID: 23850044
[TBL] [Abstract][Full Text] [Related]
14. Association Between CYP2C19 Loss-of-Function Allele Status and Efficacy of Clopidogrel for Risk Reduction Among Patients With Minor Stroke or Transient Ischemic Attack.
Wang Y; Zhao X; Lin J; Li H; Johnston SC; Lin Y; Pan Y; Liu L; Wang D; Wang C; Meng X; Xu J; Wang Y;
JAMA; 2016 Jul; 316(1):70-8. PubMed ID: 27348249
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China.
Jia DM; Chen ZB; Zhang MJ; Yang WJ; Jin JL; Xia YQ; Zhang CL; Shao Y; Chen C; Xu Y
Stroke; 2013 Jun; 44(6):1717-9. PubMed ID: 23640828
[TBL] [Abstract][Full Text] [Related]
16. Genetic Polymorphisms and Clopidogrel Efficacy for Acute Ischemic Stroke or Transient Ischemic Attack: A Systematic Review and Meta-Analysis.
Pan Y; Chen W; Xu Y; Yi X; Han Y; Yang Q; Li X; Huang L; Johnston SC; Zhao X; Liu L; Zhang Q; Wang G; Wang Y; Wang Y
Circulation; 2017 Jan; 135(1):21-33. PubMed ID: 27806998
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of ex vivo high on-treatment platelet reactivity on antiplatelet therapy after transient ischemic attack or ischemic stroke on the PFA-100(®) and VerifyNow(®).
Kinsella JA; Tobin WO; Cox D; Coughlan T; Collins R; O'Neill D; Murphy RP; McCabe DJ
J Stroke Cerebrovasc Dis; 2013 Oct; 22(7):e84-92. PubMed ID: 22981273
[TBL] [Abstract][Full Text] [Related]
18. Carriage of cytochrome 2C19 polymorphism is associated with risk of high post-treatment platelet reactivity on high maintenance-dose clopidogrel of 150 mg/day: results of the ACCEL-DOUBLE (Accelerated Platelet Inhibition by a Double Dose of Clopidogrel According to Gene Polymorphism) study.
Jeong YH; Kim IS; Park Y; Kang MK; Koh JS; Hwang SJ; Kwak CH; Hwang JY
JACC Cardiovasc Interv; 2010 Jul; 3(7):731-41. PubMed ID: 20650435
[TBL] [Abstract][Full Text] [Related]
19. Effect of high-dose clopidogrel according to CYP2C19*2 genotype in patients undergoing percutaneous coronary intervention- a systematic review and meta-analysis.
Zhang L; Yang J; Zhu X; Wang X; Peng L; Li X; Cheng P; Yin T
Thromb Res; 2015 Mar; 135(3):449-58. PubMed ID: 25511576
[TBL] [Abstract][Full Text] [Related]
20. Protocol for the comparison of triflusal and clopidogrel in secondary prevention of stroke based on cytochrome P450 2C19 genotyping (MASETRO study): A multicenter, randomized, open-label, parallel-group trial.
Han SW; Kim YJ; Ahn SH; Seo WK; Yu S; Oh SH; Kim YN; Lee KY;
Int J Stroke; 2016 Jun; 11(4):485-91. PubMed ID: 26763917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
